^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/03/2018
Excerpt:
"Patients with BCR-ABL1-like ALL and ABL-class fusions have the promising prospect
of being sensitive to tyrosine kinase inhibitors, similar to those harboring the BCR-ABL1 gene rearrangement..."
